158. 結節性硬化症 Tuberous sclerosis Clinical trials / Disease details
臨床試験数 : 112 / 薬物数 : 71 - (DrugBank : 19) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05059327 (ClinicalTrials.gov) | March 3, 2021 | 20/8/2021 | Basimglurant in Children, Adolescents, and Young Adults With TSC | A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults With Uncontrolled Seizures Associated With Tuberous Sclerosis Complex | Tuberous Sclerosis Complex | Drug: Basimglurant with crossover to Placebo;Drug: Placebo with crossover to Basimglurant | Noema Pharma AG | NULL | Recruiting | 5 Years | 30 Years | All | 54 | Phase 2 | United States;Australia;India;Israel;Italy;Poland;Spain;Turkey;United Kingdom |